Tranexamic acid reduces hidden blood loss in the treatment of intertrochanteric fractures with PFNA: a single-center randomized controlled trial

Table 2 Comparison of postoperative clinical outcomes between the TXA group and NS group

Variables	TXA study group (n = 37)	NS study group (n = 40)	P value
Surgical blood loss (mL)	128.85 ± 123.18	98.30 ± 59.10	0.31
Postoperative day 2 drainage. (mL)	89.50 ± 44.77	89.73 ± 33.30	0.98*
Hemoglobin preop. (g/L)	109.50 ± 15.07	112.15 ± 13.31	0.51*
Hemoglobin postop. day 1 (g/L)	102.70 ± 13.18	115.27 ± 60.93	0.37*
Hemoglobin postop. day 3 (g/L)	101.05 ± 11.91	100.30 ± 12.54	0.83*
Hematocrit preop. (%)	32.63 ± 4.28	33.79 ± 3.83	0.31*
Hematocrit postop. day 1 (%)	30.53 ± 3.81	31.15 ± 3.80	0.56*
Hematocrit postop. day 3(%)	30.23 ± 3.23	29.34 ± 5.87	0.54
Estimated visible RBC loss day 3 (mL)	69.26 ± 44.77	58.55 ± 22.10	0.33*
Transfusion rate (%)	11/39 (28.20%)	23/41 (56.09%)	0.01^†
Transfusion units (U)	24	56
Estimated total RBC loss day 3 (mL)	279.35 ± 209.11	417.89 ± 289.56	0.049*
Estimated hidden RBC loss day 3 (mL)	210.09 ± 202.14	359.35 ± 290.12	0.049*

*Two-sided Student’s t test; †chi-squared test; TXA tranexamic acid, NS normal-saline

ISSN: 1749-799X